ACS and MRA award $2.6 million for research focused on reducing immunotherapy side effects

Share on facebook
Share on twitter
Share on linkedin
Share on email
Share on print

The American Cancer Society and the Melanoma Research Alliance selected the first group of scientists to receive newly established research grants to investigate how to reduce side effects resulting from cancer treatments with checkpoint inhibitors.

To access this subscriber-only content please log in or renew your subscription.

Looking for IP Login? Our IP Login system is now automatic. If your institution has a site license, please log in from on site or via your VPN to access this content.

Login Subscribe

YOU MAY BE INTERESTED IN

Login